Alivus Life Sciences block deal: Promoter Nirma sells over 28 lakh shares worth Rs 390 crore; Norges Bank, Helios MF among buyers
Nirma sold 28.46 lakh Alivus Life Sciences shares worth Rs 390 crore through a block deal at Rs 1,370 apiece. Norges Bank, Bandhan MF and others bought shares as Alivus reported strong Q2FY27 earnings growth.
By Kumar Gaurav, ETMarkets.com |
Agencies
Nirma trims its Alivus Life Sciences stake through a Rs 390 crore block deal, attracting institutional buyers amid strong quarterly earnings and expanding profitability.
Promoter and fast-moving consumer goods (FMCG) player Nirma Limited sold 28.46 lakh shares of Alivus Life Sciences worth nearly Rs 390 crore through a block deal on Friday, November 6, with Norges Bank, Bandhan Mutual Fund, Helios Mutual Fund and other investors picking up the shares at Rs 1,370 apiece, according to NSE data.
Nirma sold 28,46,300 shares at Rs 1,370 per share, taking the total transaction value to approximately Rs 390 crore.
Nirma held 9,18,96,285 shares, representing a 74.85% stake in Alivus Life Sciences, at the end of the September quarter of FY27 (Q2FY27), according to the company's exchange filing.
Following Friday's transaction, Nirma's holding is estimated to have declined to 8,90,49,985 shares, or approximately 72.53%, assuming no other changes in its shareholding. The transaction would reduce Nirma's stake by around 2.32 percentage points.
On the buying side, Bandhan Mutual Fund emerged as one of the largest participants, purchasing a total of 8,55,971 shares across multiple transactions. Param Capital bought 7,29,729 shares, while Setu Securities purchased 4,10,000 shares.
Other buyers included Subhkam Ventures I, which acquired 2,50,000 shares, Sanshi Fund I with 2,00,100 shares, and Norges Bank, on account of the Government Pension Fund Global, which bought 1,83,000 shares. Helios Mutual Fund purchased a combined 2,17,500 shares across two transactions.
The block deal took place at Rs 1,370 per share, at a discount to the stock's closing price on Friday.
Alivus Life Sciences shares settled at Rs 1,480.60 apiece on the NSE, declining 1.1% from their previous close of Rs 1,497.20. During the session, the stock moved in a range of Rs 1,403.40 to Rs 1,523.20.
Despite Friday's decline, the stock has delivered returns of 62.17% so far in 2026. The company had a market capitalisation of Rs 18,206.54 crore on the NSE.
Alivus Life Sciences Q2FY27 results
The block deal comes shortly after Alivus Life Sciences reported a strong financial performance for the September quarter on October 29.
The company reported a 16% year-on-year increase in revenue to Rs 6,820 million in Q2FY27. Net profit (PAT) rose 51.3% to Rs 1,968 million, while EBITDA increased 47% to Rs 2,851 million.
Revenue from the company's non-GPL business grew 20.8% year-on-year, with the segment contributing 79% of overall revenue. Growth was supported by demand across Europe, Japan, North America, Latin America and other markets.
The company's gross margin stood at 64.4%, expanding 670 basis points year-on-year and 420 basis points sequentially, supported by a favourable product mix.
EBITDA margin improved to 41.8%, up 880 basis points year-on-year and 520 basis points quarter-on-quarter, driven by better operational efficiencies and product mix. PAT margin expanded to 28.9%, rising 680 basis points year-on-year.
Alivus also generated free cash flow of Rs 2,702 million during the quarter. Its cash and cash equivalents, including short-term investments, stood at Rs 10,116 million as of September 30, 2026.
Commenting on the performance, Yasir Rawjee, Managing Director and Chief Executive Officer of Alivus Life Sciences, said Q2FY27 was another strong quarter, with revenue growth supported by healthy demand across key markets and contributions from recent launches.
He added that the company's non-GPL business maintained its growth momentum, while its contract development and manufacturing organisation (CDMO) business witnessed a meaningful pick-up during the quarter.
Rawjee said improving business mix and operational efficiencies had contributed to stronger profitability. The company's ongoing capacity expansion and healthy development pipeline also provide confidence in sustaining growth momentum, he added.
Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
Nirma sold 28,46,300 shares at Rs 1,370 per share, taking the total transaction value to approximately Rs 390 crore.
Nirma held 9,18,96,285 shares, representing a 74.85% stake in Alivus Life Sciences, at the end of the September quarter of FY27 (Q2FY27), according to the company's exchange filing.
Following Friday's transaction, Nirma's holding is estimated to have declined to 8,90,49,985 shares, or approximately 72.53%, assuming no other changes in its shareholding. The transaction would reduce Nirma's stake by around 2.32 percentage points.
On the buying side, Bandhan Mutual Fund emerged as one of the largest participants, purchasing a total of 8,55,971 shares across multiple transactions. Param Capital bought 7,29,729 shares, while Setu Securities purchased 4,10,000 shares.
Other buyers included Subhkam Ventures I, which acquired 2,50,000 shares, Sanshi Fund I with 2,00,100 shares, and Norges Bank, on account of the Government Pension Fund Global, which bought 1,83,000 shares. Helios Mutual Fund purchased a combined 2,17,500 shares across two transactions.
ADVERTISEMENT
The block deal took place at Rs 1,370 per share, at a discount to the stock's closing price on Friday.
Alivus Life Sciences shares settled at Rs 1,480.60 apiece on the NSE, declining 1.1% from their previous close of Rs 1,497.20. During the session, the stock moved in a range of Rs 1,403.40 to Rs 1,523.20.
Despite Friday's decline, the stock has delivered returns of 62.17% so far in 2026. The company had a market capitalisation of Rs 18,206.54 crore on the NSE.
Alivus Life Sciences Q2FY27 results
ADVERTISEMENT
The block deal comes shortly after Alivus Life Sciences reported a strong financial performance for the September quarter on October 29.
The company reported a 16% year-on-year increase in revenue to Rs 6,820 million in Q2FY27. Net profit (PAT) rose 51.3% to Rs 1,968 million, while EBITDA increased 47% to Rs 2,851 million.
ADVERTISEMENT
Revenue from the company's non-GPL business grew 20.8% year-on-year, with the segment contributing 79% of overall revenue. Growth was supported by demand across Europe, Japan, North America, Latin America and other markets.
The company's gross margin stood at 64.4%, expanding 670 basis points year-on-year and 420 basis points sequentially, supported by a favourable product mix.
EBITDA margin improved to 41.8%, up 880 basis points year-on-year and 520 basis points quarter-on-quarter, driven by better operational efficiencies and product mix. PAT margin expanded to 28.9%, rising 680 basis points year-on-year.
Alivus also generated free cash flow of Rs 2,702 million during the quarter. Its cash and cash equivalents, including short-term investments, stood at Rs 10,116 million as of September 30, 2026.
Commenting on the performance, Yasir Rawjee, Managing Director and Chief Executive Officer of Alivus Life Sciences, said Q2FY27 was another strong quarter, with revenue growth supported by healthy demand across key markets and contributions from recent launches.
He added that the company's non-GPL business maintained its growth momentum, while its contract development and manufacturing organisation (CDMO) business witnessed a meaningful pick-up during the quarter.
Rawjee said improving business mix and operational efficiencies had contributed to stronger profitability. The company's ongoing capacity expansion and healthy development pipeline also provide confidence in sustaining growth momentum, he added.
Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
